JS InnoPharm, LLC Report issue

For profit Phase 1
Founded: Naperville IL United States (2011)

Organization Overview

First Clinical Trial
2020
NCT04418167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

JS InnoPharm, LLC

Active Ingredients

Drugs in Phase 1 Trials (2)

dabrafenib (tafinlar) (1 trial)

jsi-1187 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2